Brett King, MD, PhD

home / authors / brett-king-md-phd

Articles

Optimizing Patient Outcomes with JAK Inhibitors

Brett King, MD, PhD;Alexandra K. Golant, MD

January 19th 2023

Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.

Efficacy and Safety of JAK inhibitors for AD

Brett King, MD, PhD;Alexandra K. Golant, MD

January 19th 2023

Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.

Role of Disease Severity in Topical vs Systemic AD Treatment

Brett King, MD, PhD;Alexandra K. Golant, MD

January 19th 2023

Drs Alexandra Golant and Brett King discuss the role that atopic disease severity and treatment resistance play in the selection of oral vs systemic treatment for their patients.

Expert Perspective on the Care of Patients with Atopic Dermatitis

Brett King, MD, PhD;Alexandra K. Golant, MD

January 19th 2023

Brett King, M.D, Ph.D and Alexandra Golant M.D comment on their considerations on the management of patients suffering from atopic dermatitis, highlighting the importance of body surface area and patient preference in treatment selection.

Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

Raj Chovatiya, MD, PhD;Neal Bhatia, MD;Alexandra K. Golant, MD ;Brett King, MD, PhD

December 23rd 2022

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

Raj Chovatiya, MD, PhD;Neal Bhatia, MD;Alexandra K. Golant, MD ;Brett King, MD, PhD

December 22nd 2022

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

Raj Chovatiya, MD, PhD;Neal Bhatia, MD;Alexandra K. Golant, MD ;Brett King, MD, PhD

December 21st 2022

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

Raj Chovatiya, MD, PhD;Neal Bhatia, MD;Alexandra K. Golant, MD ;Brett King, MD, PhD

December 20th 2022

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

Raj Chovatiya, MD, PhD;Neal Bhatia, MD;Alexandra K. Golant, MD ;Brett King, MD, PhD

December 19th 2022

In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Continuing Medical Education: 3 Things You Should Know About Managing Alopecia Areata

Brett King, MD, PhD

October 24th 2022

Alopecia areata can have devastating effects on patients, but a greater understanding of its pathophysiology has led to the development of new treatment options.